CLEVELAND, June 14 DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that medical technology company Endosense has awarded DATATRAK the first two studies in the EFFICAS study series. The EFFICAS studies are intended to demonstrate that the use of contact force control during cardiac ablation utilizing Endosense's TactiCath® force-sensing catheter results in superior outcomes as compared to ablations performed without a force sensor. Outcomes data from the EFFICAS I and II studies will help in the design of future EFFICAS studies with clinical endpoints.
Advertisement
"The EFFICAS study data will be a very important addition to Endosense's large and growing scientific armamentarium proving the comparative value of contact force-sensing in the catheter ablation treatment of cardiac arrhythmias, and it is critical that the data be well documented and managed from day one," said Hendrik Lambert, vice-president, clinical affairs and regulatory, Endosense. "We look forward to working with DATATRAK as we execute and report on these exciting studies."
Advertisement
"We are delighted that Endosense has entrusted DATATRAK with the first two studies in the EFFICAS series," said Laurence Birch, DATATRAK's Chairman of the Board. "Endosense's decision to invest in DATATRAK ONE(TM) early in the clinical development of the EFFICAS studies will yield lower trial costs throughout the life of the pipeline. We applaud Endosense's decision to choose our unified technology platform. While our competitors are striving to follow our lead in developing end-to-end solutions, DATATRAK is pushing the industry forward by driving clinical trial efficiencies."
About Endosense
Founded in Geneva in 2003, Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The company has pioneered the use of contact force measurement in catheter ablation, with the development of its proprietary Touch+® sensor technology. Endosense's flagship product is the TactiCath, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure.
Endosense is backed by Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie. For more information, visit http://www.endosense.com.
About DATATRAK International, Inc.
DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery in DATATRAK ONE(TM), the seamless delivery of product and services. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical(TM) software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK has offices located in Cleveland, Ohio, and Bryan, Texas. For more information, visit http://www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's quarterly report filed with the Pink OTC Markets on May 12, 2010 announcing its results for the three month period ending March 31, 2010. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
DATATRAK International, Inc. and DATATRAK eClinical(TM) and certain other trademarks and logos appearing on this press release are trademarks or registered trademarks of DATATRAK International, Inc. or its affiliates. All other brands and trademarks used herein are or may be trademarks of, and are used to identify other products or services of, their respective owners.
SOURCE DATATRAK International, Inc.
